Publication of Prospectus

RNS Number : 9767S
GlaxoSmithKline PLC
06 December 2012
 

Publication of Supplementary Prospectus

 

The following Supplementary Prospectus dated 5 December 2012, supplementing the Base Prospectus dated 5 September 2012, has been approved by the UK Listing Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GlaxoSmithKline Capital Inc. £15,000,000,000 Euro Medium Term Note Programme

A copy of the Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for viewing at:

http://www.morningstar.co.uk/uk/NSM.

The Supplementary Prospectus will also be available for viewing at:

http://www.gsk.com/reports-and-publications.html

 

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

 

Enquiries:

UK Media enquiries:

David Mawdsley

Sarah Spencer

(020) 8047 5502

(020) 8047 5502

 

European Analyst/Investor enquiries:

Sally Ferguson

Gary Davies

Ziba Shamsi

(020) 8047 5543

(020) 8047 5503

(020) 8047 3289

BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS AND BASE PROSPECTUS

Please note that the information contained in the Supplementary Prospectus and the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PDILFFLVFLLRIIF

Companies

GSK (GSK)
UK 100

Latest directors dealings